Considering that ER-positive cancers make up approximately 70% of breast cancers and that treatment outcomes differ according to molecular subtype (luminal A vs. B) [31], we attempted to conduct HR-MAS MRS metabolic profiling with a larger number CNB samples of ER-positive cancers in this study. This evidence concerns the gene ESR1 and breast cancer.